AUD 0.01
(-14.29%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 | 3.67 Million AUD | 30.95% |
2023 | 2.8 Million AUD | 57.42% |
2022 | 1.78 Million AUD | 24.43% |
2021 | 1.43 Million AUD | 34.59% |
2020 | 1.06 Million AUD | -0.88% |
2019 | 1.07 Million AUD | -6.28% |
2018 | 1.14 Million AUD | -45.09% |
2017 | 2.08 Million AUD | 9.07% |
2016 | 1.91 Million AUD | 8.63% |
2015 | 1.76 Million AUD | 17.69% |
2014 | 1.49 Million AUD | -47.94% |
2013 | 2.87 Million AUD | -15.99% |
2012 | 3.42 Million AUD | -23.94% |
2011 | 4.5 Million AUD | 329.26% |
2010 | 1.04 Million AUD | -48.58% |
2009 | 2.03 Million AUD | -62.67% |
2008 | 5.46 Million AUD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.45 Million AUD | 0.0% |
2024 FY | 3.61 Million AUD | 28.64% |
2024 Q4 | 2.15 Million AUD | 0.0% |
2023 Q2 | 1.13 Million AUD | 0.0% |
2023 Q4 | 1.67 Million AUD | 0.0% |
2023 FY | 2.8 Million AUD | 57.42% |
2022 Q2 | 337.7 Thousand AUD | 0.0% |
2022 Q4 | 822.95 Thousand AUD | 0.0% |
2022 FY | 1.78 Million AUD | 24.43% |
2021 Q2 | 681.2 Thousand AUD | 0.0% |
2021 FY | 1.43 Million AUD | 34.59% |
2021 Q4 | 760.82 Thousand AUD | 0.0% |
2020 Q4 | 338.01 Thousand AUD | 0.0% |
2020 Q2 | 727.47 Thousand AUD | 0.0% |
2020 FY | 1.06 Million AUD | -0.88% |
2019 Q2 | 539.15 Thousand AUD | 0.0% |
2019 Q4 | 493.74 Thousand AUD | 0.0% |
2019 FY | 1.07 Million AUD | -6.28% |
2018 FY | 1.14 Million AUD | -45.09% |
2018 Q2 | 251.3 Thousand AUD | 0.0% |
2018 Q4 | 377.84 Thousand AUD | 0.0% |
2017 Q2 | 805.36 Thousand AUD | 0.0% |
2017 FY | 2.08 Million AUD | 9.07% |
2016 FY | 1.91 Million AUD | 8.63% |
2016 Q2 | 946.41 Thousand AUD | 0.0% |
2015 Q2 | 628.96 Thousand AUD | 0.0% |
2015 FY | 1.76 Million AUD | 17.69% |
2014 Q1 | 738.48 Thousand AUD | 0.0% |
2014 FY | 1.49 Million AUD | -47.94% |
2014 Q4 | 528.78 Thousand AUD | 28.31% |
2014 Q3 | 412.1 Thousand AUD | -63.65% |
2014 Q2 | 1.13 Million AUD | 53.51% |
2013 Q3 | 738.48 Thousand AUD | 34.61% |
2013 FY | 2.87 Million AUD | -15.99% |
2013 Q4 | 738.48 Thousand AUD | 0.0% |
2013 Q2 | 548.61 Thousand AUD | -54.37% |
2013 Q1 | 1.2 Million AUD | 0.0% |
2012 Q2 | 1.2 Million AUD | 6.81% |
2012 Q3 | 1.2 Million AUD | 0.0% |
2012 Q4 | 1.2 Million AUD | 0.0% |
2012 FY | 3.42 Million AUD | -23.94% |
2012 Q1 | 1.12 Million AUD | 0.0% |
2011 FY | 4.5 Million AUD | 329.26% |
2011 Q1 | 262.21 Thousand AUD | 0.0% |
2011 Q3 | 1.12 Million AUD | 0.0% |
2011 Q4 | 1.12 Million AUD | 0.0% |
2011 Q2 | 1.12 Million AUD | 329.26% |
2010 Q2 | 262.21 Thousand AUD | -70.79% |
2010 Q3 | 262.21 Thousand AUD | 0.0% |
2010 Q1 | 897.71 Thousand AUD | 0.0% |
2010 Q4 | 262.21 Thousand AUD | 0.0% |
2010 FY | 1.04 Million AUD | -48.58% |
2009 Q1 | 1.4 Million AUD | 0.0% |
2009 Q4 | 897.71 Thousand AUD | 0.0% |
2009 FY | 2.03 Million AUD | -62.67% |
2009 Q3 | 897.71 Thousand AUD | 0.0% |
2009 Q2 | 897.71 Thousand AUD | -36.28% |
2008 Q3 | 1.4 Million AUD | 0.0% |
2008 FY | 5.46 Million AUD | 0.0% |
2008 Q4 | 1.4 Million AUD | 0.0% |
2008 Q2 | 1.4 Million AUD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
AdAlta Limited | 6.76 Million AUD | 45.662% |
Biome Australia Limited | 7.91 Million AUD | 53.504% |
Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1129.291% |
Biotron Limited | 5.11 Million AUD | 28.026% |
Acrux Limited | 8.55 Million AUD | 56.978% |
Alterity Therapeutics Limited | 23.4 Million AUD | 84.285% |
Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -511.21% |
BTC Health Limited | -1.03 Million AUD | 454.056% |
Chimeric Therapeutics Limited | 19.76 Million AUD | 81.392% |
CSL Limited | 7.56 Billion AUD | 99.951% |
Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 93.467% |
Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 88.247% |
Immutep Limited | 42.87 Million AUD | 91.421% |
Neuren Pharmaceuticals Limited | 32.69 Million AUD | 88.75% |
Noxopharm Limited | 7 Million AUD | 47.453% |
Prescient Therapeutics Limited | 10.89 Million AUD | 66.25% |
Race Oncology Limited | 14.77 Million AUD | 75.096% |
Starpharma Holdings Limited | 22.81 Million AUD | 83.878% |
Tissue Repair Ltd | 6.66 Million AUD | 44.825% |
EZZ Life Science Holdings Limited | 39.57 Million AUD | 90.705% |
Anatara Lifesciences Ltd | 710.21 Thousand AUD | -417.924% |
Bio-Gene Technology Limited | 2.76 Million AUD | -33.226% |
Zelira Therapeutics Limited | 5.94 Million AUD | 38.163% |
Patrys Limited | 4.93 Million AUD | 25.438% |
Orthocell Limited | 15.36 Million AUD | 76.067% |
Imugene Limited | 135.09 Million AUD | 97.277% |
PYC Therapeutics Limited | 60.91 Million AUD | 93.962% |
Proteomics International Laboratories Limited | 892.14 Thousand AUD | -312.309% |
Cynata Therapeutics Limited | 11.12 Million AUD | 66.932% |
Arovella Therapeutics Limited | 10.78 Million AUD | 65.894% |
Nanollose Limited | 12.5 Thousand AUD | -29324.702% |
Invex Therapeutics Ltd | 3.34 Million AUD | -9.938% |
NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -87.174% |
Amplia Therapeutics Limited | 8.43 Million AUD | 56.395% |
Island Pharmaceuticals Limited | 4.12 Million AUD | 10.835% |
Nyrada Inc. | 4.55 Million AUD | 19.248% |
Telix Pharmaceuticals Limited | 269.26 Million AUD | 98.634% |
Dimerix Limited | 25.64 Million AUD | 85.656% |
PharmAust Limited | 6.65 Million AUD | 44.744% |
Hexima Limited | 1 Million AUD | -264.648% |
AnteoTech Limited | 12.18 Million AUD | 69.817% |
Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 94.35% |
Recce Pharmaceuticals Ltd | 21.68 Million AUD | 83.037% |
Avecho Biotechnology Limited | 4.54 Million AUD | 19.075% |
Actinogen Medical Limited | 22.77 Million AUD | 83.846% |
Immuron Limited | 9.13 Million AUD | 59.746% |
Argenica Therapeutics Limited | 8.26 Million AUD | 55.517% |